Quick Answer
Kalaris Therapeutics, Inc. reported Diluted EPS of $2.85 per share (loss) for fiscal year 2025.
Kalaris Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.85 | +94.5% |
| 2024 | -$51.77 | -23.0% |
| 2023 | -$42.09 | -1813.2% |
| 2022 | -$2.20 | +19.7% |
| 2021 | -$2.74 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.64 | +97.7% | -4.9% |
| June 30, 2025 | -$0.61 | +85.7% | +75.8% |
| March 31, 2025 | -$2.52 | +3.1% | +91.1% |
| September 30, 2024 | -$28.16 | -7120.5% | -561.0% |
| June 30, 2024 | -$4.26 | -787.5% | -63.8% |
| March 31, 2024 | -$2.60 | -490.9% | -566.7% |
| September 30, 2023 | -$0.39 | +22.0% | +18.7% |
| June 30, 2023 | -$0.48 | +30.4% | -9.1% |
- Kalaris Therapeutics, Inc. showed an increase of +94.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Kalaris Therapeutics, Inc.’s diluted eps has declined by 4.0% (from $2.74 per share (loss) to $2.85 per share (loss)).
- The most recent figure is from Kalaris Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: